EZH2 and prostate carcinoma: To investigate the biochemical and biological consequences of EZH2 and HDAC inhibitors in prostate cancer, we used a panel of cell lines including PC3 (AR-), C42B (AR independent), LnCAP (AR dependent), and PT-09 cells (mouse, AR independent).